tiprankstipranks
Trending News
More News >
Materialise NV (MTLS)
:MTLS
Advertisement

Materialise (MTLS) AI Stock Analysis

Compare
927 Followers

Top Page

MTLS

Materialise

(NASDAQ:MTLS)

Select Model
Select Model
Select Model
Neutral 63 (OpenAI - 4o)
Rating:63Neutral
Price Target:
$6.50
▲(7.62% Upside)
Materialise's overall stock score reflects stable financial performance with strong gross margins and a conservative balance sheet. However, challenges in revenue growth and profitability, along with a high P/E ratio, suggest overvaluation. The technical analysis indicates positive momentum, but macroeconomic challenges in key segments temper the outlook.

Materialise (MTLS) vs. SPDR S&P 500 ETF (SPY)

Materialise Business Overview & Revenue Model

Company DescriptionMaterialise (MTLS) is a global leader in 3D printing and additive manufacturing solutions, focusing on transforming the way products are designed and manufactured across various industries, including healthcare, aerospace, automotive, and consumer goods. The company offers a comprehensive suite of software solutions, 3D printing services, and manufacturing technologies, enabling clients to innovate and optimize their production processes. Materialise's core products include software for 3D printing preparation and management, as well as a range of additive manufacturing services that cater to both prototyping and production needs.
How the Company Makes MoneyMaterialise generates revenue through multiple streams, primarily from software licensing and service fees. The software segment includes sales from its proprietary software solutions that assist in the design and preparation of 3D printing processes, with recurring revenue from licenses and subscriptions. Additionally, the company earns significant income from its 3D printing services, providing custom manufacturing solutions for clients across various industries. Materialise also engages in partnerships with major players in the 3D printing ecosystem, enhancing its market reach and capabilities, further contributing to its revenue. The company's focus on innovation and expansion into new markets, such as healthcare applications, also plays a critical role in driving its financial growth.

Materialise Earnings Call Summary

Earnings Call Date:Oct 28, 2025
(Q3-2025)
|
Next Earnings Date:Mar 11, 2026
Earnings Call Sentiment Neutral
The call highlighted strong performance in the Medical segment, achieving record revenue and growth in medical devices and services. However, challenges in the Software and Manufacturing segments, particularly due to macroeconomic conditions and sector-specific downturns, tempered the overall positive outlook. While the net cash position improved, manufacturing profitability remains a concern.
Q3-2025 Updates
Positive Updates
Record Revenue in Materialise Medical
Materialise Medical posted an all-time revenue record of EUR 33.3 million, growing by more than 10% compared to the third quarter of last year.
Strong Growth in Medical Devices and Services
Continued growth in both direct and partner sales in the Medical Devices and Services segment, with medical software and device sales growing by 6% and 12%, respectively.
Net Cash Position Increase
The company further increased its net cash position to EUR 67.7 million, driven by strong free cash flow.
Progress in Defense Sector
Materialise made progress in the defense sector, leveraging capabilities built for aerospace, and engaged with major primes at various defense and security trade exhibitions.
Negative Updates
Revenue Decline in Software and Manufacturing Segments
Revenues from Software and Manufacturing segments declined by 7% and 17%, respectively, due to macroeconomic headwinds.
Impact of Macroeconomic and Geopolitical Uncertainty
Macroeconomic and geopolitical uncertainties continued to put pressure on sales volumes, especially in the U.S. markets.
Manufacturing Segment EBITDA Loss
The adjusted EBITDA of the Manufacturing segment ended negative this quarter at minus EUR 0.8 million.
Continued Manufacturing Challenges
The manufacturing segment faced continued headwinds, particularly from the automotive sector, impacting operational results.
Company Guidance
During the Q3 2025 Materialise Financial Results Conference Call, the company provided guidance for the full year 2025, maintaining their revenue forecast in the range of EUR 265 million to EUR 280 million and adjusted EBIT between EUR 6 million and EUR 10 million. Despite macroeconomic challenges affecting the Software and Manufacturing segments, the Medical segment achieved a 10% revenue increase, reaching EUR 33.3 million, and an impressive adjusted EBITDA margin exceeding 30%. Consolidated revenue for the quarter was EUR 66.3 million, reflecting a 2% growth compared to Q2 2025 but a 3.5% decline year-over-year. The company's net cash position improved to EUR 67.7 million, driven by strong free cash flow, despite a decrease in Software and Manufacturing segment revenues by 7% and 17%, respectively. The firm emphasized cost control measures and anticipated recovery in European markets and the automotive sector as key to boosting profitability.

Materialise Financial Statement Overview

Summary
Materialise shows consistent revenue growth and improving profitability metrics. The balance sheet is strong with low leverage, but there are potential liquidity constraints due to decreased cash reserves. Cash flow generation is stable, though free cash flow is volatile.
Income Statement
Materialise has shown a consistent growth trajectory in total revenue over the years, with a notable increase from $170.4M in 2020 to $269.9M in TTM 2025. The gross profit margin remains strong at 56.3% in TTM, and the net profit margin has improved to 3.6% from negative levels in 2022. However, EBIT margin has decreased to 2.3% in TTM, indicating pressures on operational efficiency. EBITDA margin is solid at 11.8%, showing stable earnings before non-cash expenses.
Balance Sheet
The company maintains a healthy balance sheet with a debt-to-equity ratio of 0.15, suggesting a conservative leverage approach. The equity ratio stands at 63.7% in TTM, indicating strong equity financing. Return on Equity has improved to 3.9% in TTM, reflecting better profitability. However, the decrease in cash and short-term investments over the years indicates potential liquidity constraints.
Cash Flow
Operating cash flow to net income ratio is robust at 3.2 in TTM, highlighting strong cash generation relative to net income. However, free cash flow growth has been volatile, with TTM free cash flow at $5.8M, a slight improvement from previous periods. The free cash flow to net income ratio is lower at 0.6, indicating less cash available for expansion or dividends.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue265.54M266.76M256.13M232.02M205.45M170.45M
Gross Profit150.16M150.82M145.13M128.76M117.28M94.00M
EBITDA31.66M31.24M30.09M23.44M36.72M13.75M
Net Income5.63M13.44M6.72M-2.15M13.15M-7.27M
Balance Sheet
Total Assets404.38M396.34M396.63M411.26M413.41M327.67M
Cash, Cash Equivalents and Short-Term Investments116.71M102.30M127.57M140.87M196.03M111.54M
Total Debt53.67M41.28M64.40M80.98M99.11M115.11M
Total Liabilities154.97M147.84M160.04M182.33M180.83M194.56M
Stockholders Equity249.49M248.58M236.65M228.96M232.58M133.10M
Cash Flow
Free Cash Flow1.54M5.08M8.40M-64.00K14.12M12.33M
Operating Cash Flow22.77M31.46M20.16M24.71M25.84M29.98M
Investing Cash Flow-21.17M-28.59M-11.04M-53.92M-13.13M-28.27M
Financing Cash Flow-8.98M-27.64M-22.37M-24.87M71.16M-16.89M

Materialise Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price6.04
Price Trends
50DMA
5.53
Positive
100DMA
5.53
Positive
200DMA
5.76
Positive
Market Momentum
MACD
0.14
Positive
RSI
51.76
Neutral
STOCH
39.66
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTLS, the sentiment is Neutral. The current price of 6.04 is above the 20-day moving average (MA) of 6.01, above the 50-day MA of 5.53, and above the 200-day MA of 5.76, indicating a neutral trend. The MACD of 0.14 indicates Positive momentum. The RSI at 51.76 is Neutral, neither overbought nor oversold. The STOCH value of 39.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MTLS.

Materialise Risk Analysis

Materialise disclosed 72 risk factors in its most recent earnings report. Materialise reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Materialise Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
$286.51M45.3314.48%0.49%10.53%21.98%
$356.77M57.342.21%3.63%-48.48%
$37.18B12.37-10.20%1.83%8.50%-7.62%
$399.64M-55.85%4.06%57.50%
$336.64M-3.84%-3.60%48.15%
$242.30M1.3811.68%-17.17%497.89%
$211.81M-105.81%-10.85%-15.09%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MTLS
Materialise
5.94
-0.23
-3.73%
TRAK
ReposiTrak
15.24
-3.87
-20.25%
API
Agora
3.60
0.66
22.45%
CMRC
Commerce.com
4.83
-0.61
-11.21%
MKTW
MarketWise
14.56
3.94
37.10%
NRDY
Nerdy
1.09
0.16
17.20%

Materialise Corporate Events

Materialise NV Reports Q3 2025 Financial Results Amid Economic Challenges
Oct 28, 2025

On October 28, 2025, Materialise NV reported its financial results for the third quarter of 2025, highlighting a 2.2% increase in total consolidated revenue compared to the previous quarter, though a 3.5% decrease from the same period in 2024. The Materialise Medical segment achieved a record quarterly revenue growth of 10.3% year-over-year, despite macroeconomic challenges impacting overall revenue, particularly in the Manufacturing segment. The company maintained strong cash flow and a positive net result, with a net profit of 1,848 kEUR. CEO Brigitte de Vet-Veithen emphasized the company’s focus on cost control and continued R&D investments to ensure future growth, while acknowledging ongoing geopolitical and economic uncertainties.

Materialise NV Reports Q3 2025 Financial Results with Focus on Medical Segment Growth
Oct 28, 2025

Materialise NV reported a decrease in total revenue by 3.5% for the third quarter of 2025 compared to the same period in 2024, with a notable increase in their Medical segment revenue by 10.3%. Despite the revenue decline, the company saw an increase in cash flow from operating activities and a stronger net cash position. However, the operating result and net profit both decreased compared to the previous year, reflecting challenges in their Software and Manufacturing segments. The company’s strategic focus on the Medical segment is evident with increased R&D investments, which may influence future growth in this area.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 28, 2025